Evaluation of the Impact of Transit Troubles in Patients Undergoing Peritoneal Dialysis (TransDiPe)

Vichy Hospital Center

Status

Enrolling

Conditions

Peritoneal Dialysis Complication

Constipation

Treatments

Other: Questionnaires

Study type

Observational

Funder types

Other

Identifiers

NCT04102527

CHV 2018-1

Details and patient eligibility

About

Patients with Terminal Chronic Kidney Disease undergoing Peritoneal Dialysis (PD) often have pathophysiological factors that promote chronic constipation. It affects the quality of life of Patients undergoing PD in a much greater way than for hemodialysis patients because it causes complications, mechanical and infectious associated with the transmural migration of enteral bacteria, with an impact on patient morbidity and survival of the technique. In addition, it should be noted that PD patients often take potentially constipants treatments such as phosphorus chelators, calcium inhibitors, opiates, iron preparation and antidepressants. Taking these drugs decreases gastric acidity, which is associated with an increased prevalence of peritonitis.

In this context, a significant lack of literature, specifically studying the risk factors for constipation in Terminal Chronic Kidney Disease patients treated with DP and the correlation with mechanical and infectious complications, is improvable.

Full description

Patients included in this trial will be monitored as part of the usual management of their pathology, a Terminal Chronic Kidney Disease treated by the Peritoneal Dialysis technique.

During this treatment, patients will be follow every 2 months in consultation in the Metabolic Diseases Department of the Hospital of Vichy.

These consultations include:

Pre-selection consultation/Inclusion (visit to J0 -3 months)
Half-yearly review (visit J0, visit at 12 months and visit at 24 months)
Simple consultation (visits to 2, 4, 8, 10, 14, 16, 20, 22 months)
Annual review (visits at 6 and 18 months)

In this prospective trial, there is no intervention on the patient; They will only have to complete questionnaires on their intestinal transit (Charlson Scale, Katz Scale, Neurological Functional Score, Intestinal Function Index, Severity Score for constipation, Bristol Scale, Constipation Assessment Scale, Constipation Risk Assessment Scale). No minimal risk and constraint is identified, excluding our trial from the category of interventional research. The category 3 (non-interventional trial) of the jardé classification is therefore accepted.

Enrollment

180 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients with TerminalChronic Kidney disease undergoing Peritoneal Dialysis for at least three months in stable condition,
Patients who are able to complete the study questionnaires every 2 months,
Cooperation and understanding sufficient to comply with the requirements of the study,
Ability to understand the French language for an informed understanding of the information and non-opposition forms,
Affiliation with the French Social Security scheme.

Exclusion criteria

Patients whose peritoneal dialysis catheter is considered non-functional at J0,
Patients with a medical and/or surgical history considered by the investigator or his representative to be not compatible with the trial,
Patients with unstabilized progressive pathology at the time of inclusion at J0,
Patients who are mentally incapacitated to answer questionnaires,
Women of childbearing age who do not use an effective contraceptive method, pregnant or lactating women.
Patients with legal protection measures (curatorship, guardianship, etc.).